Future studies will focus on elucidating the therapeutic potential for blocking IGFBP2 and/or STAT3 in vivo to reduce SHH medulloblastoma tumor growth and prevent metastasis, thereby improving patient survival and quality of life, as well as perhaps permitting reduced exposure to radiation and toxic chemotherapies given the established roles of IGFBP2 in resistance to therapy in other types of cancer. The gene discussed is STAT3; the disease is cancer.